The secret’s out about a trendy autism treatment — now it may be impossible to find
Leucovorin, a supportive care drug, has gained popularity as a treatment for autism, leading to a significant increase in prescriptions. The drug, which may help improve communication and reduce hyperactivity in children with autism, has become difficult for parents to obtain due to high demand. Despite its popularity, leucovorin is not officially approved for autism spectrum disorder by the FDA.
- ▪Leucovorin prescriptions increased by over 2,000% in three years due to media attention and public endorsements.
- ▪A clinical trial found that one-third of young participants with autism showed significant improvements when taking leucovorin.
- ▪Doctors are struggling to meet the demand for leucovorin, with some unable to schedule new patients until 2028.
New York Post files mainly under news. We currently carry 10,427 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/05/18/health/secrets-out-about-a-trendy-autism-treatment-making-it-difficult-to-find/ |
| Publication time | Mon, 18 May 2026 16:52:51 -0400 |
| Retrieval time | 2026-05-18T20:54:56.946Z |
| Last seen | 2026-05-18T20:54:56.946Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Amem2o9pYppf |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Medicine The secret’s out about a trendy autism treatment — now it may be impossible to find By Rachel Sacks Published May 18, 2026, 4:52 p.m. ET See more of our coverage in your search results. Add The New York Post on Google It’s a dose of disappointment. A supportive care drug that may help ease hyperactivity and improve speech and communication in children with autism has become so popular that desperate parents may have trouble getting their hands on it. Leucovorin — a reduced form of folate or vitamin B9, an essential nutrient our bodies can’t make on their own — took center stage last fall when the White House touted it as an “amazing” treatment for autism. With autism affecting about 1 in 31 children, many parents are trying to get a treatment that’s recently spiked in popularity.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
